跳至主要内容
临床试验/NCT03400878
NCT03400878已完成4 期

Evaluating the Non-specific Effects of Different BCG Strains in Guinea-Bissau: Randomized Trial of the Impact on Early-life Hospital Admissions and Deaths

Bandim Health Project2 个研究点 分布在 1 个国家目标入组 17,505 人开始时间: 2017年10月14日最近更新:
适应症
干预措施

试验速览

阶段
4 期
状态
已完成
入组人数
17,505
试验地点
2
主要终点
Hospital admission at National Hospital Simão Mendes Pediatric Ward

研究概览

简要总结

Background: Investigators at Bandim Health Project (BHP, www.bandim.org) in Guinea-Bissau have shown in several randomized trials that the Bacille-Calmette-Guérin (BCG) vaccine against tuberculosis (TB) is associated with reduced mortality in the first months of life.

BCG is a live attenuated vaccine, which means that it consists of active tuberculosis bacteria that are not capable of infecting a human with TB. BCG has been grown and maintained at many different laboratories all over the world using slightly different laboratory techniques. Due to the accumulation of genetic mutations in the different BCG strains, many variants of the vaccine exists today. These have different properties when it comes to immune response, side effects, protection against TB and scar formation. The BCG scar status after vaccination is a good marker for the non-specific effects of the vaccine; among BCG-vaccinated infants, those with a BCG scar have improved survival. The investigators hypothesize that the different types of BCG vary in terms of the strength of the non-specific effects and thus the impact on overall morbidity and mortality.

In the trial, the investigators will compare the two most widely used BCG strains in the world, BCG-Russia and BCG-Japan, with respect to their non-specific effects on morbidity and mortality. As an addition, the investigators will study the effect of maternal BCG vaccination on the subsequent effect of BCG-vaccination in the offspring, since there are indications that the maternal BCG scar status primes for a stronger non-specific response in the offspring.

详细描述

In the trial, the investigators will compare the two currently most widely used BCG strains in the world, BCG-Russia and BCG-Japan, with respect to their non-specific effects on morbidity and mortality.

The investigators propose a 3-year randomized controlled trial (RCT) at the maternity ward of the main hospital Simão Mendes (HNSM) in urban Bissau, Guinea-Bissau, comparing 1:1 BCG-Japan vs. BCG-Russia in 15,600 infants with respect to morbidity and mortality. Additionally, the investigators will use this large study to test the role of the mother's BCG scar status for the overall health effect of BCG in her child.

Objective

The investigators aim to investigate the following hypotheses:

  1. Compared with BCG-Russia, vaccination with BCG-Japan is associated with fewer admissions and deaths.
  2. The effect of BCG in the child is more beneficial if the mother has a BCG scar.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Basic Science
盲法
Double (Care Provider, Outcomes Assessor)

入排标准

年龄范围
— 至 42 Days(Child)
性别
All
接受健康志愿者

入选标准

  • Newborn, unvaccinated infants identified at the maternity ward and ready to be discharged

排除标准

  • Infants above 6 weeks (>42 days) of age; Infants with gross malformation; Infants that are acutely ill

研究组 & 干预措施

BCG-RUSSIA

Active Comparator

BCG-RUSSIA Infants randomised to receive BCG-RUSSIA at discharge from the Maternity Ward will receive one 0.05 ml dose Mycobacterium bovis BCG live attenuated vaccine BCG-RUSSIA (Serum Institute of India, Pune, India) by intradermal injection in the left deltoid region.

干预措施: BCG-Russia (Biological)

BCG-JAPAN

Active Comparator

Infants randomised to receive BCG-JAPAN at discharge from the Maternity Ward will receive one 0.05 ml dose of Mycobacterium bovis BCG live attenuated BCG-JAPAN vaccine (Japan BCG Laboratory, Tokyo, Japan) by intradermal injection in the left deltoid region.

干预措施: BCG-Japan (Biological)

结局指标

主要结局

Hospital admission at National Hospital Simão Mendes Pediatric Ward

时间窗: 6 weeks

Number of participants admitted to the Pediatric Ward of National Hospital Simão Mendes within up to 6 weeks (42 days) of age. BHP documents all admissions at the ward.

次要结局

  • Mortality, stratified by parental BCG scar status(6 months)
  • Mortality(6 months)
  • In-hospital case-fatality rate at National Hospital Simão Mendes Pediatric Ward(6 weeks)
  • In-hospital case-fatality rate at Pediatric Ward(6 months)
  • Hospital admission at National Hospital Simão Mendes Pediatric Ward(6 months)
  • In-hospital case-fatality rate at National Hospital Simão Mendes' Pediatric Ward, stratified by parental BCG scar status(6 months)
  • Hospital admission at National Hospital Simão Mendes' Pediatric Ward, stratified by parental BCG scar status(6 months)
  • Mortality(6 weeks)
  • Mortality, stratified by parental BCG scar status(6 weeks)
  • Hospital admission at National Hospital Simão Mendes' Pediatric Ward, stratified by parental BCG scar status(6 weeks)
  • In-hospital case-fatality rate at National Hospital Simão Mendes' Pediatric Ward, stratified by parental BCG scar status(6 weeks)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验

进行中(未招募)
1 期
A Study exploring the Biologic Effects and Biomarkers of Nivolumab in combination with Ipilimumab in Subjects with Non-Small Cell Lung Cancer (NSCLC)MedDRA version: 20.1Level: LLTClassification code 10080083Term: Advanced lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Treatment-Naive Stage IV or recurrent Non-Small Cell Lung Cancer (NSCLC)MedDRA version: 20.0Level: PTClassification code 10059515Term: Non-small cell lung cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
EUCTR2018-000462-11-ESBristol-Myers Squibb International Corporation250
进行中(未招募)
1 期
A Study exploring the Biologic Effects and Biomarkers of Nivolumab in combination with Ipilimumab in Subjects with Non-Small Cell Lung Cancer (NSCLC)Treatment-Naive Stage IV or recurrent Non-Small Cell Lung Cancer (NSCLC)MedDRA version: 21.1Level: PTClassification code 10059515Term: Non-small cell lung cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.1Level: LLTClassification code 10080083Term: Advanced lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
EUCTR2018-000462-11-BEBristol-Myers Squibb International Corporation250
进行中(未招募)
1 期
A Study exploring the Biologic Effects and Biomarkers of Nivolumab incombination with Ipilimumab in Subjects with Non-Small Cell Lung Cancer(NSCLC)Treatment-Naive Stage IV or recurrent Non-Small Cell Lung Cancer(NSCLC)MedDRA version: 20.0Level: LLTClassification code 10007096Term: Cancer of lungSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10059515Term: Non-small cell lung cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
EUCTR2018-000462-11-ITBRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATIO250
进行中(未招募)
1 期
A Study exploring the Biologic Effects and Biomarkers of Nivolumab in combination with Ipilimumab in Subjects with Non-Small Cell Lung Cancer (NSCLC)Treatment-Naive Stage IV or recurrent Non-Small Cell Lung Cancer (NSCLC)MedDRA version: 21.1Level: PTClassification code 10059515Term: Non-small cell lung cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.1Level: LLTClassification code 10080083Term: Advanced lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
EUCTR2018-000462-11-ROBristol-Myers Squibb International Corporation250
已完成
2 期
An Exploratory Study of the Biologic Effects and Biomarkers of Nivolumab in combination with Ipilimumab in Subjects with Treatment-Naive Stage IV or recurrent Non-Small Cell Lung Cancer (NSCLC)10038666Non-small cell lung cancer
NL-OMON55382Bristol-Myers Squibb10